Drug Target Review

APRIL 7, 2025

The development of PoLiPa technology marks a new era in membrane protein drug discovery, rendering otherwise difficult targets accessible to structural biology, biophysical assays and other screening technologies. This stability enables the application of hit identification approaches such as fragment-based screening (FBS).

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

NOVEMBER 1, 2023

We are part of the ICR’s PhD-student programme, which is exciting, because with PhD-student projects we have the ability to probe the more academic questions related to our drug discovery science. I think as a researcher you have to be honest and transparent about your data, and always do the best science that you possibly can do.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Molecular Design

SEPTEMBER 18, 2024

When examining differences between IC 50 values for the same combination of target and inhibitor it's worth bearing in mind that interference with assay read-outs tends to be more of an issue at high concentration (this is why biophysical assays tend to be favored for screening fragments).

Biochemical Assays 68

Biochemical Assays Biophysical Assays Drugs Cell Based Assays 68

Drug Target Review

JANUARY 16, 2025

As computational chemists, medicinal chemists, biophysicists and biologists collaborate closely and combine biophysical data with computational methods, macrocyclic therapeutic development is becoming increasingly feasible and efficient. He has a PhD in Computer Science from Carnegie Mellon University.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52